Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Global central banks show mixed outlook, with Fed and BoE decisions hinging on data and policy shifts.
Microsoft signs massive AI deal with IREN, boosting its AI infrastructure and capacity.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Global central banks show mixed outlook, with Fed and BoE decisions hinging on data and policy shifts.
Microsoft signs massive AI deal with IREN, boosting its AI infrastructure and capacity.